Clinical ink has a proven track record of managing complex site data collection. The company has prioritized its study solutions to deliver faster time to market, greater ease of use, and better patient experience. Teckro supports informed decisions at the point of care with an intuitive, native mobile app loved by investigators around the world. Together, Clinical ink and Teckro will propel a new era of engagement and usability for site partners.

Expected to be available to site partners globally, the collaboration yields immediate benefits including:

• Immediate Execution of Inclusion/Exclusion Review and eConsent Facilitation
  Accelerate the process of obtaining electronic consent, reduce administrative burden, and expedite trial enrollment
   
• One Native App for All Protocols
  Eliminate the site burden of managing dozens of passwords to different study sponsor portals
   
• Decentralized Experience for Engaging with Study Experts
  Provide immediate answers at the point of care for investigators and site staff
   
• Interconnected Digital Protocol and Seamless Transition to Data Collection
  Eliminate the risk of the wrong protocol version being used by sites and streamline data capture
   
• Streamlined Communication for Enhanced Site-Sponsor Collaboration
  Open new opportunities for sponsors to proactively communicate with sites and create a direct feedback loop

“We are partnering with Teckro to bring about a paradigm shift in site user engagement and ease of use in clinical trials,” says Jonathan Goldman, MD, CEO at Clinical ink. “Combining our expertise in complex site data collection with Teckro’s decision support app sets us up to improve site partners’ user experience, compliance, and study timelines.”

“By collaborating with Clinical ink for complex site data collection, we are shaping a new era of simplicity and efficiency in clinical trials,” adds Gary Hughes, Co-Founder and CEO at Teckro. “We can further empower investigators and research staff to navigate study answers seamlessly, streamline data capture, and facilitate enhanced collaboration between sites and sponsors.”

About Clinical ink

Clinical ink is the global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the standards for data precision and usher in a new generation of clinical trials.

About Teckro

Teckro is the interconnected digital protocol that delivers immediate answers from study resources and experts anytime, anywhere. A single mobile app for all protocols, Teckro is the go-to resource for informed study decisions to orchestrate better patient care. Available on Apple and Android devices, Teckro is used by thousands of investigators around the world for all phases, any trial setting, and every therapeutic area.

The post Clinical ink and Teckro Partner to Enhance Site User Engagement appeared first on Clinical ink.

Horsham, PA, June 8th, 2022 – Megan Petrylak, Executive Vice President of Customer Delivery at Clinical ink, and Jonathan Andrus with Society for Clinical Data Management will be leading the session “Collection of Quality Endpoint Data in a Decentralized Trial in Complex Indications: The Practical and Logistical Challenges” at DIA 2022 in Chicago on Tuesday, June 21st from 11:00-12:00 pm (CDT). 

When using sophisticated assessments in clinical research, sponsors must capture both structured and unstructured data – on site and remotely. Using disease-specific decentralized clinical trials as examples, Megan and Jonathan will discuss how remotely deployed data capture technology helps to manage both logistically as well as therapeutically complex clinical trials. 

For over 14 years, Petrylak has held various leadership roles within the pharma industry to drive program and operational excellence. At Clinical ink, she leads key organizational initiatives to drive better outcomes for patients. 

Visit with the Clinical ink team in Booth #1701 at DIA 2022 to learn about our clinical trial digital data capture solutions. 

About Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

About DIA

For more than 50 years, DIA has been dedicated to providing a neutral and transparent global forum for the exchange of ideas and collaborations to further scientific and medical innovations. The DIA 2022 Global Annual Meeting brings industry, regulators, academics and patients together to co-create, problem-solve, and discuss global and local challenges facing professionals in the life sciences community.

The post Clinical ink Discusses How Remotely Deployed Data Capture Technology Solves Challenges in Complex, Decentralized Clinical Trials appeared first on Clinical ink.

Horsham, Pa. May 25, 2022 — Clinical ink, a global life science technology company, was nominated for Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT) during the organization’s 29^th annual Enterprise Awards, held May 24, 2022. 

Clinical ink was recognized for pioneering and continually innovating direct data capture technologies, which allow for the measurement of clinical trial patients both in and outside the clinic. Notably, earlier in 2022 the company announced research that strengthens its standing as a critical partner in advancing clinical development for Parkinson’s disease, via the collection of patient data via sensors and at-home wearable assessments. 

Clinical ink was nominated by a panel of judges consisting of executives from the area’s largest life science and healthcare companies, healthcare and technology focused investors, and startup executives. 

“We are incredibly honored to be among the nominees,” says Chief Executive Officer Ed Seguine. “At Clinical ink, our work is rooted in enabling clinical discovery by bringing data, technology, and patient science together. We are proud to be recognized for our technological prowess, as well as our deep industry knowledge and scientific expertise. We will only continue to advance our offerings, ensuring that our partners can better power patient outcomes.” 

Over the past five years, Clinical ink has experienced 40% annual revenue growth. By consistently delivering technology solutions that allow for the collection of complex clinical data, the company has established relationships with the largest and most innovative pharmaceutical sponsors in the industry.  

About Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience. 

The post Clinical ink nominated for Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT) appeared first on Clinical ink.